After-Hours Movers 12/12: (SRPT) (IHRT) (ADBE) Higher; (UTI) (ASPU) (ORCL) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Adobe (ADBE) PT Raised to $334 at Griffin Securities
December 13, 2019 7:59 AM ESTGriffin Securities analyst Jay Vleeschhouwer raised the price target on Adobe (NASDAQ: ADBE) to $334.00 (from $330.00) while maintaining a Buy rating.
... MoreSarepta Therapeutics (SRPT) PT Raised to $190 at Credit Suisse
December 13, 2019 7:44 AM ESTCredit Suisse analyst Martin Auster raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $190.00 (from $185.00) while maintaining an Outperform rating after the FDA approved Vyondys 53.
The company plans to price the drug at parity with Exondys 51 or >$600,000 for a... MoreSarepta Therapeutics (SRPT) PT Raised to $215 at RBC Capital; 'Vynodys Approval A Big Win'
December 13, 2019 6:19 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $215.00 (from $200.00) while maintaining an Outperform rating following approval of Vyondys 53/golodirsen.
The analyst commented, "We view tonight's approval of Vyondys 53/golodirsen as a significant win for SRPT,... More
